Journal of Pharmaceutical Health Care and Sciences最新文献

{"title":"Practical and clinical significance of the pharmacist-led antimicrobial stewardship.","authors":"Takumi Umemura","doi":"10.1186/s40780-026-00551-9","DOIUrl":"10.1186/s40780-026-00551-9","url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) undermines clinical care. Thus, ensuring appropriate antimicrobial therapy is crucial in global and national AMR countermeasures. This narrative review aimed to summarize pharmacist-led antimicrobial stewardship interventions in Japan and discuss their practical and clinical significance across inpatient, outpatient, and community settings. In inpatient care, antimicrobial stewardship programs (ASPs), usually embedded within antimicrobial stewardship teams and supported by national policies and reimbursement incentives, have consistently reduced broad-spectrum antibiotic use (e.g., carbapenems). ASPs improve microbiological indicators such as Pseudomonas aeruginosa susceptibility while maintaining patient safety. The evidence of ASP efficiency spans large tertiary hospitals that consider post-prescription review with feedback and expanded prospective audit-and-feedback. In addition, small-to-medium hospitals that adopt pharmacist-led programs have demonstrated improved key process measures (culture acquisition, de-escalation, and duration of therapy), as well as optimized clinical outcomes in selected high-risk subgroups. Given that outpatient oral antibiotics account for a substantial proportion of total consumption, ASPs are increasingly being recognized as an essential approach. Reported pharmacist-led interventions include monitoring and feedback to high-prescription departments, regimen optimization based on susceptibility data, and dental outpatient programs that shift prescriptions from third-generation cephalosporins toward guideline-recommended penicillins. At the community level, regional educational outreach with surveillance feedback and peer-comparison approaches, as well as community pharmacy-based prescription optimization, have demonstrated meaningful shifts toward narrower-spectrum agents. Pharmacist-led ASPs in Japan have largely benefitted inpatients, whereas outpatient and community stewardship remains an essential frontier requiring enhanced implementation and rigorous assessment of patient-centered outcomes.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12983564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Storage stability of hospital-prepared mianserin suppositories: evaluation of residual active ingredient content and bacteriological contamination under different storage conditions.","authors":"Rei Tanaka, Tomoe Ichikawa, Junya Sato","doi":"10.1186/s40780-026-00543-9","DOIUrl":"10.1186/s40780-026-00543-9","url":null,"abstract":"<p><p>BACKGROUND: Mianserin suppositories are a hospital preparation usable for patients who cannot take oral medication. However, data on the stability of hospital preparations are limited. Therefore, this study investigated the stability of mianserin suppositories over time and the appropriate storage methods. METHODS: For the long-term chemical stability testing, five conditions were compared: RL; room temperature (15–30°C) under ambient light, RD; room temperature in the dark, CL; cool temperature (2–8°C) under ambient light, CD; cool temperature in the dark, and FD; frozen temperature (−20°C) in the dark. High-performance liquid chromatography (HPLC) was used to compare time-dependent component contents at 0, 2, 4, 8, 16, and 24 weeks (n = 5). Microbial limit tests for total aerobic microorganisms and fungi were conducted using the agar plate dilution method immediately after preparation and after 24 weeks in RL, and after 24 weeks at FD (n = 4). RESULTS: A gradual decline was observed under all storage conditions. The residual content rate (mean ± standard error (SE)) after 24 weeks was as follows: RL, 96.2 ± 0.3%; RD, 96.2 ± 0.2%; CL, 97.0 ± 0.3%; CD, 97.3 ± 0.3%; and FD, 98.3 ± 0.2%. Under all conditions—immediately after preparation, after 24 weeks of RL, and after 24 weeks of FD—the total aerobic microbial count was ≤1000 colony-forming units (CFU)/g, and the total fungal count was ≤100 CFU/g. CONCLUSION: The results showed that the residual content remained satisfactory above 95% from immediately after preparation through 24 weeks under all storage conditions, ranging from RL to FD. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12977472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biphasic dysglycemia induced by pentamidine and detected by intermittently scanned continuous glucose monitoring: a case report of a possible drug-drug interaction with clopidogrel and literature review.","authors":"Yuki Nakano, Noriko Kuhara, Rintaro Sogawa, Hisanari Yasukochi, Yusuke Okayama, Misato Motoya, Hidehiro Ishii, Hirotsugu Hasuwa, Chisato Shimanoe","doi":"10.1186/s40780-026-00549-3","DOIUrl":"10.1186/s40780-026-00549-3","url":null,"abstract":"<p><p>BACKGROUND: Pentamidine is an alternative treatment for Pneumocystis pneumonia (PCP) in patients who are intolerant to sulfamethoxazole-trimethoprim; however, its use is limited by serious adverse effects, including glycemic fluctuations. Herein, we report a case in which intermittently scanned continuous glucose monitoring (isCGM) was used to monitor real-time glycemic fluctuations during pentamidine therapy, enabling successful completion of treatment. To contextualize this case, we also conducted a targeted literature review of pentamidine-induced glucose dysregulation. CASE PRESENTATION: An 86-year-old Japanese man undergoing immunosuppressive therapy for rheumatoid arthritis was diagnosed with PCP and initially treated with sulfamethoxazole-trimethoprim. Because of suspected adverse effects of sulfamethoxazole-trimethoprim, the patient was switched to intravenous pentamidine as second-line therapy. Given the risks associated with advanced age, abnormal kidney function, and concomitant use of clopidogrel, an organic cation transporter 1 (OCT1) inhibitor that may affect pentamidine disposition, glycemic monitoring was initiated using isCGM. The patient experienced nocturnal hypoglycemia soon after initiating pentamidine treatment, which persisted after pentamidine discontinuation. He subsequently developed marked hyperglycemia associated with impaired endogenous insulin secretion, necessitating temporary regular insulin administration and sitagliptin combination therapy. His glycemic control gradually stabilized, and recovery of pancreatic β-cell function was confirmed by increased urinary C-peptide levels. In a literature review of 83 reports published between 1995 and 2025, only nine cases of pentamidine-associated dysglycemia were identified, and this was the only case that demonstrated biphasic glucose dysregulation with both hypoglycemia and hyperglycemia. CONCLUSION: This case demonstrates that biphasic glucose dysregulation associated with pentamidine (early hypoglycemia followed by delayed-onset hyperglycemia) can be captured using isCGM. Real-time glucose monitoring during pentamidine therapy enabled early intervention and safe completion of treatment. Glycemic monitoring using isCGM may be beneficial in patients receiving pentamidine, especially those with abnormal kidney function, older patients, or those receiving concomitant OCT1 inhibitor therapy. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12977656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of target initial teicoplanin trough concentration attainment in patients with hematological malignancies: a retrospective cohort study.","authors":"Kazuki Deguchi, Norihiro Sakurai, Toya Matsui, Mayuko Itoya, Makoto Miyoshi, Hiroshi Kawaguchi, Yasutaka Nakamura","doi":"10.1186/s40780-026-00550-w","DOIUrl":"10.1186/s40780-026-00550-w","url":null,"abstract":"<p><p>BACKGROUND: Teicoplanin (TEIC) is frequently used at Osaka Metropolitan University Hospital to treat infections caused by gram-positive cocci in patients with hematological malignancies. However, in certain cases, the initial trough concentrations failed to reach the target level, despite appropriate loading doses. Therefore, this study aimed to identify the factors associated with achieving target concentrations based on the initial trough level following TEIC loading in patients with hematological malignancies. METHODS: We retrospectively analyzed patients with hematological malignancies treated with TEIC between January 2016 and December 2022. Patients were classified into a target trough attainment group (trough ≥ 15 µg/mL) and a non-attainment group (trough < 15 µg/mL) according to the initial trough concentration measured on day 4 after administering the loading doses. Demographics, clinical laboratory data, TEIC dosing, and concomitant medications were compared between groups. Factors independently associated with the target trough concentration were assessed using multivariate logistic regression analysis. RESULTS: Among the 176 patients, 90 (51%) achieved the target trough concentration, while 86 (49%) did not. Multivariate analysis identified febrile neutropenia, history of bone marrow transplantation within 30 days, presence or absence of tacrolimus (TAC) coadministration, and cumulative TEIC dose over the first 3 days as independent predictors of target attainment. The target concentration attainment rate was only 22% among patients with febrile neutropenia who received a TEIC cumulative loading dose of < 40 mg/kg over the first 3 days after initiation and did not receive TAC coadministration. CONCLUSIONS: Achieving adequate TEIC concentrations early in therapy is critical for the successful treatment of immunocompromised patients with hematological malignancies. Our findings indicated that the likelihood of target trough concentration attainment markedly reduced in patients with multiple risk factors for subtherapeutic exposure. Accordingly, higher doses should be administered, particularly to patients with these factors. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12973770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Day 8 monocyte and lymphocyte counts as a novel and early predictor for discontinuation in gynecologic cancer patients receiving paclitaxel and carboplatin therapy: a retrospective observational study.","authors":"Hiroaki Watanabe, Keita Hirai, Hirofumi Komachiya, Takafumi Naito","doi":"10.1186/s40780-026-00547-5","DOIUrl":"10.1186/s40780-026-00547-5","url":null,"abstract":"<p><p>BACKGROUND: Maintaining optimal treatment intensity is essential for therapeutic efficacy in gynecological malignancies undergoing paclitaxel plus carboplatin (TC) chemotherapy; however, myelosuppression frequently results in treatment delay or interruption, which can compromise long-term outcomes. While previous research has predominantly focused on pre-treatment laboratory values and late-onset adverse events, there is a crucial gap in identifying early, actionable biomarkers. This study sought to evaluate the utility of post-treatment values measured at an early time point (Day 8) to facilitate timely and proactive supportive interventions. METHODS: This retrospective analysis included 242 patients who underwent TC chemotherapy. Patients who discontinued therapy for reasons other than myelosuppression (e.g., allergic reactions or patient choice) were excluded from the final analyses. The primary outcome was treatment interruption (delay or cessation) due to persistence of myelosuppression during the first cycle. Predictive modeling assessed baseline, day 8, and combined hematological factors (including neutrophil, monocyte, and lymphocyte counts, and their derived ratios). Predictive performance was evaluated using multivariate logistic regression and receiver operating characteristic (ROC) curve analyses. RESULTS: The model incorporating both pre- and post-treatment laboratory values demonstrated superior predictive performance, evidenced by a significantly higher area under the ROC curve than the model utilizing only pre-treatment factors (0.82 vs. 0.73, P = 0.011). Decision tree analysis identified critical cutoff points for post-treatment laboratory values: monocyte counts below 51/µL and lymphocyte counts below 994/µL on day 8 after chemotherapy. Additionally, a pre-treatment neutrophil count of 2,795/µL was identified as a significant risk factor. CONCLUSIONS: Early post-treatment hematological indices, particularly the day 8 monocyte and lymphocyte counts, were identified as more robust predictors of chemotherapy interruption due to myelosuppression, in addition to pre-treatment indices. These findings suggest that routine monitoring and proactive supportive interventions guided by these specific early post-treatment markers should be implemented in clinical pharmacy practice to enhance treatment continuity and optimize patient outcomes. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12964638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative clinical features of antibiotic-associated Kounis syndrome and non-Kounis allergic coronary events: a disproportionality analysis using U.S. Food and Drug Administration Adverse Event Reporting System.","authors":"Ichiro Nakakura, Yutaro Mukai, Atsuki Hosoda, Naohiro Ohara, Kaori Yamanishi, Takaya Uno, Satoshi Yokoyama, Kouichi Hosomi, Yoshiko Une","doi":"10.1186/s40780-026-00545-7","DOIUrl":"10.1186/s40780-026-00545-7","url":null,"abstract":"<p><strong>Background: </strong>Kounis syndrome (KS) is an acute coronary syndrome (ACS) triggered by allergic reactions and is frequently associated with antibiotic exposure. However, patient characteristics of antibiotic-associated KS cases are not well described. Some cases with KS-consistent symptoms may instead be reported as antibiotic-associated allergic coronary events (non-KS) without proper diagnosis. Characterizing these non-KS events may improve the accurate diagnosis of KS. This study explores the clinical features of antibiotic-associated KS and non-KS allergic coronary events in the FDA Adverse Event Reporting System (FAERS) and generates hypotheses regarding potential underdiagnosis and improved recognition of KS.</p><p><strong>Methods: </strong>FAERS reports (September 2012-December 2024) were screened for allergic symptoms (SMQ: Anaphylactic reaction; Hypersensitivity) and ACS (SMQ: Acute myocardial infarction) with antibiotics listed as suspected drugs. After exclusions, 459 cases (KS: 205; non-KS: 254) were included. Extracted variables included demographics, comorbidities, drug use (ATC classification), and outcomes. Logistic regression identified factors independently associated with non-KS classification.</p><p><strong>Results: </strong>Non-KS group exhibited higher rates of cardiac comorbidities, diabetes, and mortality (all p < 0.05). Among suspected antibiotics, penicillins were the only class more frequently reported in KS cases (42% vs. 30%, p = 0.010). In the multivariable analysis, factors independently associated with non-KS classification included female sex (odds ratio [OR] = 1.804), fatal outcomes (OR = 4.320), and use of quinolones (OR = 11.108), aminoglycosides (OR = 3.480), renin-angiotensin agents (OR = 2.608), analgesics (OR = 2.055), and polypharmacy (OR = 3.314) (area under the curve = 0.815).</p><p><strong>Conclusions: </strong>These exploratory findings indicate that non-KS allergic coronary events, characterized by higher comorbidities, mortality, and proportion of cases reporting the use of quinolones or aminoglycosides, may suggest a potential relationship between non-KS coronary events and KS underdiagnosis, warranting further prospective investigation.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12958633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of family pharmacist continuity with patient-reported satisfaction in patients with metastatic cancer: a nationwide cross-sectional study.","authors":"Atsunobu Sagara, Tomofumi Watanabe, Tomoya Abe, Takatsune Shimizu, Shunsuke Shirozu, Hiroyuki Terakado","doi":"10.1186/s40780-026-00548-4","DOIUrl":"10.1186/s40780-026-00548-4","url":null,"abstract":"<p><p>BACKGROUND: Patients with metastatic cancer face prognostic uncertainty and substantial psychological stress, requiring support for both physical and mental health. We examined the association of family pharmacist continuity with patient-reported satisfaction, and secondarily whether higher satisfaction is associated with greater treatment hope, in a nationwide sample in Japan. METHODS: A nationwide online survey was conducted on 481 participants in Japan who were in contact with a pharmacist and diagnosed with metastatic cancer. The participants were categorized into groups based on the continuity of contact with their family pharmacist before and after their primary cancer diagnosis. We assessed the association of family pharmacist continuity with patient-reported satisfaction using the MISS-21J, and examined the satisfaction–treatment hope association with Spearman’s rank correlation. RESULTS: The group with the same family pharmacist before and after the primary cancer diagnosis (Same) and the group in which the family pharmacist changed but remained involved before and after cancer diagnosis (Changed) showed significantly higher distress relief and rapport (a sense of mutual trust and understanding with the pharmacist) scores on the MISS-21J than the group without a family pharmacist from pre to post cancer diagnosis (None) (p < 0.001). Additionally, a strong correlation (rs = 0.740, p < 0.001) was observed between the MISS-21J total score and treatment hope score. CONCLUSIONS: Continuous pharmacist involvement with patients, regardless of the change in pharmacists before the primary cancer diagnosis, shows the potential to contribute to psychological support and improved treatment hope in patients with metastatic cancer. While causal inference cannot be made from this cross-sectional study, establishing a long-term support system by a family pharmacist may play an important role in promoting patient-centered cancer care. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12958496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study.","authors":"Tatsuya Ohtsubo, Kazuhiro Yamamoto, Saori Matumoto, Kaori Ito, Yuzuka Sasa, Kosuke Tomishima, Satoshi Dote, Katsuya Makihara, Yoshinori Wakasugi, Tsutomu Mitsuie, Kouhei Yamagiwa, Kazuo Sato, Hiroki Hasegawa, Nobuhiko Uoshima, Yumi Kitahiro, Kanji Tomogane","doi":"10.1186/s40780-026-00546-6","DOIUrl":"10.1186/s40780-026-00546-6","url":null,"abstract":"<p><p>BACKGROUND: Premedication with corticosteroids is recommended for prophylaxis against infusion-related reactions (IRRs) caused by obinutuzumab despite a lack of solid evidence regarding the dose of corticosteroids. METHODS: The incidence rates of IRR in the high-dose and low-dose corticosteroid groups were investigated and compared using Student’s t-test.Univariable and multivariable logistic regression analyses were performed on patients to explore the risk of developing IRRs with obinutuzumab. RESULTS: The incidence of IRRs in the high-dose and low-dose corticosteroid groups at the initial administration of obinutuzumab was 27.0% (41/152) and 48.4% (31/64), respectively, indicating that the high-dose group had a lower incidence of IRRs (p = 0.002). The incidence of IRRs at the initial administration of obinutuzumab was significantly associated with the administration of first-generation histamine 1 receptor antagonist (OR = 3.31, 95% CI: 1.16–9.47; reference: second-generation histamine 1 receptor antagonist), hydrocortisone (OR = 7.21, 95% CI: 1.57–33.15; reference: dexamethasone), and methylprednisolone (OR = 3.99, 95% CI :1.13–14.10; reference: dexamethasone), although no association was found with the lower dose of corticosteroids. CONCLUSIONS: Although no association was found between corticosteroid dosage and IRR when considering multiple factors, dexamethasone may be a better option than hydrocortisone or methylprednisolone for preventing IRR. Additionally, second-generation H1-receptor antagonists may be a better option than first-generation drugs. Certain combinations of premedications may influence infusion reaction incidence. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12958665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pharmacist-led medication therapy management on the efficacy of cancer pain control: a pre-post interventional study.","authors":"Yu Dong, Yufeng Liu, Shunfu Zheng, Li Feng","doi":"10.1186/s40780-026-00544-8","DOIUrl":"10.1186/s40780-026-00544-8","url":null,"abstract":"<p><p>BACKGROUND: Cancer pain remains a prevalent and debilitating symptom among patients with advanced malignancies, significantly compromising quality of life. While clinical guidelines for pain management exist, real-world challenges such as polypharmacy, poor adherence, and drug-related problems (DRPs) hinder effective treatment. Pharmacist-led Medication Therapy Management (MTM) offers a structured approach to address these challenges, but its role in cancer pain management remains underexplored. AIM: This study aimed to evaluate the effect of pharmacist-led MTM on cancer pain management. METHODS: A pre-post interventional study was conducted using the MTM services implemented in January 2023. RESULTS: A total of 246 patients were included in the pre-MTM group (n = 100) and MTM (n = 146) groups. Pharmacist-led MTM was associated with better cancer pain score at 30-day follow-up (3.85 ± 1.07 VS 4.85 ± 1.47, P < 0.001) and greater reduction in pain scores (1.92 ± 0.84 VS 2.81 ± 1.21, P < 0.001) compared to the pre-MTM group. In Additional, the MTM effectively identified and resolved the DRPs, achieving a resolution rate of 73.81%. A lower incidence of adverse drug reactions, including constipation, nausea, and vomiting, was observed in the MTM group (P < 0.05). Furthermore, pharmacist-led MTM was associated with a higher proportion of patients with high medication adherence, with 67.81% in the MTM group compared with 45% in the pre-MTM group (P < 0.001). Pharmacist-led MTM was associated with higher patient satisfaction with treatment (4.71 ± 1.14 vs. 3.04 ± 2.07, P < 0.001) and follow-up (3.92 ± 1.76 vs. 3.46 ± 1.70, P = 0.02) compared with the pre-MTM group. CONCLUSION: Pharmacist-led MTM plays a crucial role in optimizing cancer pain management by reducing DRPs, improving adherence, minimizing adverse drug reactions, and enhancing patient satisfaction. It is an essential component of comprehensive, individualized care that ultimately improves the clinical outcomes and quality of life of patients with cancer. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"24"},"PeriodicalIF":1.3,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12918049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Troxipide nanosuspensions prevent indomethacin‑induced gastrointestinal lesions in adjuvant-induced arthritis rats.","authors":"Kazuya Fujimoto, Hiroko Otake, Rie Tanaka, Fumihiko Ogata, Chika Fujii, Naoki Yamamoto, Naohito Kawasaki, Toshihiko Ishizaka, Takeshi Kotake, Noriaki Nagai","doi":"10.1186/s40780-026-00542-w","DOIUrl":"10.1186/s40780-026-00542-w","url":null,"abstract":"<p><p>BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for managing inflammatory disorders such as rheumatoid arthritis (RA); however, their long-term use is frequently associated with gastrointestinal (GI) complications, often leading to RA treatment discontinuation. To address this issue, we developed an oral formulation of troxipide (TRO), a pharmaceutical agent with gastroprotective properties, using nanosuspension technology to enhance its GI absorption and therapeutic efficacy. METHODS: The TRO nanosuspensions (TRO-NP@dis) were prepared by bead milling with methylcellulose (MC) as a stabilizing agent, yielding particles with an average diameter of 148 nm. An adjuvant-induced arthritis (AA) rat model, characterized by heightened susceptibility to NSAID-induced GI injury, was employed to assess pharmacokinetics and therapeutic efficacy. RESULTS: TRO-NP@dis showed improved dispersibility relative to conventional microparticle dispersions (TRO-MP@dis). Although the viscosities and zeta potentials of TRO-MP@dis and TRO-NP@dis were comparable, the solubility of TRO-NP@dis was markedly higher. Pharmacokinetic studies in rats revealed enhanced retention of TRO in the stomach, jejunum, and ileum following oral administration of TRO-NP@dis compared with TRO-MP@dis. Indomethacin (IND) administration (40 mg/kg) significantly increased the mucosal lesion area in AA rats compared to that in controls. However, the co-administration of TRO-NP@dis significantly reduced the lesion areas in the stomach, jejunum, and ileum compared to those in vehicle-treated AA rats, indicating notable protective effects. These findings suggested that TRO-NP@dis confers enhanced mucosal adhesion and retention, leading to improved therapeutic outcomes in patients with IND-induced GI injury. CONCLUSIONS: This nanosuspension-based delivery system represents a promising approach for mitigating NSAID-related GI complications in patients with RA by increasing local drug concentrations and reducing mucosal damage. </p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"23"},"PeriodicalIF":1.3,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12911231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146043951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}